Literature DB >> 2414505

Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility.

A Uchida, F Vánky, E Klein.   

Abstract

The effect of interferon (IFN) on target cell susceptibility to human natural killer (NK) cells and monocytes was analyzed in direct cell-mediated and their cytotoxic factor-mediated cytotoxicity assays. Treatment of K562 cells with IFN resulted in a decrease in their sensitivity to lysis by nonadherent lymphocytes and Percoll-purified large granular lymphocytes (LGL) when tested in a 4-hour 51Cr release assay. In contrast, the treatment did not affect the target susceptibility to monocytes purified by adherence to autologous serum-coated plastic surfaces. In the target-binding assay with LGL or monocytes the number of conjugates was not altered after IFN treatment of K562. Lymphocytes and monocytes were induced to release soluble cytotoxic factors, termed "natural killer cytotoxic factors (NKCF) and monocyte cytotoxic factors (MCF)," respectively, when co-cultured with K562. Both NKCF and MCF lysed K562 in a 48-hour microcytotoxicity assay or in an 18-hour 51Cr release assay in the presence of dactinomycin. IFN-treated K562 reduced or completely lost their ability to stimulate the release of NKCF, whereas they triggered MCF secretion as effectively as did the untreated K562. When lymphocytes or monocytes were pretreated with IFN, they released NKCF or MCF with augmented lytic activity. In contrast to the sensitivity to NK cell-mediated lysis, IFN pretreatment of K562 induced no change in their susceptibility to NKCF and MCF. When IFN was added to NKCF and MCF assays, the cytotoxicity was enhanced. The addition of IFN to K562 that had been pretreated with NKCF or MCF and washed resulted in no increase in lysis. The capacity of K562 to absorb the lytic activity of NKCF and MCF was not altered by IFN. These results indicate that IFN treatment of target cells can be used to distinguish the two distinct types of blood mononuclear cells with natural cytotoxicity, NK cells and monocytes, and that each effector cell type is stimulated to release cytotoxic factors by the different target determinant after the initial effector-target cell binding.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2414505     DOI: 10.1093/jnci/75.5.849

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

Review 1.  Histocompatibility antigens and natural killer susceptibility.

Authors:  J Peña; R Solana
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Lysing of fresh human tumor by a cytotoxic factor derived from autologous large granular lymphocytes independently of other known cytokines.

Authors:  A Uchida; T Fujimoto; Y Mizutani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing.

Authors:  H Yeoman; R A Robins
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

4.  In vitro modulation of natural killer cell activity in non-Hodgkin's lymphoma patients after therapy.

Authors:  B A Mehta; M N Satam; S H Advani; J J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.

Authors:  P M Furbert-Harris; C H Evans
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Human tumour-associated NK cells secrete increased amounts of interferon-gamma and interleukin-4.

Authors:  J Lorenzen; C E Lewis; D McCracken; E Horak; M Greenall; J O McGee
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

Review 7.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.